Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

EASL 2021: Rapid Recap by Dr. Stefan Zeuzem

June 23-26, 2021; Virtual

Hear a rapid update of the top HBV, HCV, and HDV studies from the Virtual 2021 International Liver Congress, 2021.

Stefan Zeuzem, MD
Released: July 22, 2021

Related Content

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Dr. Stacey Trooskin discusses the implementation of the simplified HCV treatment model, presented by Clinical Care Options (CCO)

Stacey Trooskin, MD, PhD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 31, 2021 Expired: August 30, 2022

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Clinical Care Options (CCO) expert commentary from George Lau, MD, on the importance of screening patients for hepatitis B prior to immunosuppressive therapy initiation

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: August 23, 2021
Educational grant provided by:
AbbVie
Antios Therapeutics
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue